Recent Updates
Recently added Catalysts
PCRX Positive Sentiment

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Key Takeaway: Pacira BioSciences, Inc. (NASDAQ: PCRX) announced its participation in the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 8, 2024. The event will feature an analyst-led fireside chat accessible via the company's investor website. Pacira aims to redefine opioid use by promoting its non-opioid treatment options, including EXPAREL®, ZILRETTA®, and iovera™. A replay of the event will be available for two weeks post-conference.
Price reaction · baseline $29.15 (2024-04-01 close) · hit after-hours · clean, no other PCRX news in the window
day 0 close · peak
-2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pacira is actively participating in a notable healthcare conference.
  • The company focuses on providing non-opioid treatment options.
  • Pacira has multiple commercial-stage non-opioid treatments available.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
5.7%
average across 5 past catalysts
Lead asset
FX006
Phase 2 · Osteoarthritis of the Shoulder

Full Press Release Details

TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Frequently Asked Questions

When is Pacira BioSciences participating in the Needham Conference?

Pacira BioSciences will participate on April 8, 2024, at 8:00 AM ET.

How can I listen to the Pacira conference event live?

The live audio can be accessed on Pacira's Events page at investor.pacira.com.

What is the purpose of Pacira BioSciences' mission?

Pacira aims to provide non-opioid options to redefine opioids as rescue therapy.

What non-opioid treatments does Pacira offer?

Pacira offers EXPAREL®, ZILRETTA®, and ioveraº® for pain management.

Where can I find more information about Pacira?

More information can be found on Pacira's website at www.pacira.com.

Last updated: Apr 2, 2024